Protection from vascular risk in diabetic hypertension

Current Hypertension Reports

Volumn 2, Issue 2, 2000, Pages 154-159

  Corry, Dalila B ^a   Tuck, Michael L ^b  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 0034170289     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0075-2     Document Type: Article

References (41)

1. The Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993, 329: 977-986.
2. Abouna GM, Al-Adnani MS, Kremer GD, et al.: Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients. Lancet 1983, 2(suppl 8362):1274-1276.
3. Peterson MR, Vine AK: Progression of retinopathy after pancreas transplantation. The University of Michigan Pancreas Transplant Evaluation Committee. Ophthalmology 1990, 97: 496-500.
4. Tuck ML, Corry DB: Pathophysiology and management of hypertension in diabetes. Annu Rev Med 1991, 42: 533-548.
5. Corry DB, Tuck ML: Hypertension and diabetes. Sem Nephrol 1991, 5: 561-570.
6. Henrion D, Laher I: Insulin potentiates norepinephrineinduced vascular tone by activation of protein kinase C and tyrosine kinase. Can J Physiol Pharmacol 1994, 72: 849-854.
7. Kelleher C, Kingston S, Barry SM, et al.: Hypertension in diabetic clinic patients and their siblings. Diabetologia 1998, 31: 76-81.
8. Ferris JB, O'Hare JA, Kelleher CM, et al.: Diabetic control and the renin-angiotensin system, catecholamines and blood pressure. Hypertension 1985, 7(suppl 2):58-63.
9. Anderson EA, Mark AL: The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 1993, 21: 136-141.
10. Yamaguchi T, Omaha K, Takayanagi R, et al.: Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine aortic endothelial cells. FEBS Lett 1990, 267: 16-18.
11. Kamal K, Du W, Mills I, Sumpio BE: Antiproliferative effect of elevated glucose in human microvascular endothelial cells. J Cell Biochem 1998, 71: 49-501.
12. Vlassara H. Brownlee M, Monague KR, et al.: Cachectin, TNF, and IL-I induced by glucose modified proteins: role in normal tissue remodeling. Science 1998, 240: 1546-1548.
13. Bucola R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87: 432-438.
14. Muntzel MS, Hamidou I, Barrett S: Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. Hypertension 1999, 33: 1135-1140.
15. Stern N, Tuck ML: Diabetes and hypertension. In Diabetes Mellitus: A Fundamental and Clinical Text. Edited by LeRoith D, Olefsky JM, Taylor S. New York: Lippincott-Raven; 1996: 357-372.
16. Marre M, Bernadet P, Gallois Y, et al.: Relationship between angiotensin 1 converting enzyme gene polymorphism, plasma levels and diabetic retinal and renal complications. Diabetes 1994, 48: 384-388.
17. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998, 317: 703-713.
18. Hansson L, Zanchetti A, Carruters SG, et al.: Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351: 1755-1762.
19. Tuomilehto J, Rastenyte D, Birkenhager WH, et al.: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340: 677-684.
20. Okubo S, Niimura F, Matsuoka T, et al.: Angiotensinogen gene null-mutant mice lack homeostatic regulation of glomerular filtration and tubular reabsorption. Kidney Int 1998, 53: 617-625.
21. Danser AH, Derkx FH, Admiraal PJ, et al.: Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994, 35: 1008-1018.
22. Wagner J, Jan Danser AH, Derkx FH, et al.: Demonstration of renin mRNA, angiotensinogen mRNA and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996, 80: 159-163.
23. Makimattila S, Summanen P, Matinlauri I, et al.: Serum total renin: an independent marker of the activity and severity of retinopathy in patients with IDDM. Br J Ophtalmol 1998, 82: 939-944.
24. Chase HP, Garg SK, Harris S, et al.: Angiotensin-converting enzyme inhibitor treatment of young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993, 25: 284-289.
25. Larsen M, Hommel E, Parving HH, Lund-Handersen H: Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990, 228: 505-509.
26. Ravid M, Savin H, Jutrin I, et al.: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993, 118: 577-581.
27. Chaturvedi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998, 351: 28-31.
28. Poulsen PL, Bek T, Ebbehloj E, et al.: 24-h ambulatory blood pressure and retinopathy in normoalbuminuric IDDM patients. Diabetologia 1998, 41: 105-110.
29. The United States Renal Data System: USRDS Annual Data Report. Bethesda: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
30. Nelson RG, Bennett PH, Beck GJ et al.: Development and progression of diabetic nephropathy in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 1996, 335: 1636-1642.
31. Neil AM, Hawkins M, Potock M, et al.: A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993, 16: 996-1003.
32. Ibrahim HN, Rosenberg ME, Greene EL, et al.: Aldosterone is a major factor in the progression of renal disease. Kidney Int 1997, 52(suppl 63): S115-S118.
33. Jacobsen P, Rossing K, Rossing P, et al.: Angiotensin converting gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998, 53: 1002-1006.
34. Freire MBS, Ji L, Onuma T, et al.: Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension 1998, 31: 896-899.
35. Brazy PC, Fitzwilliam JF: Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990, 37: 1113-1119.
36. Parving HH, Tarnow L, Rossing P: Renal protection in diabetes: an emerging role for calcium antagonists. Cardiology 1997, 88(Suppl 3):56-62.
37. US department of Health and Human Services, Public Health Service Centers for Disease Control: Surveillance for Diabetes Mellitus-United States, 1980-1989. MMWR CDC Surveill Summ 1993, 42: 334(suppl 2):1-20.
38. Miller JA, Anacta LA, Cattran DC: Impact of gender on the renal response to angiotensin II. Kidney Int 1999, 55: 278-285.
39. Koya D, King GL: Protein kinase C in diabetic renal involvement: the perspective of its inhibition. In The Kidney and Hypertension in Diabetes Mellitus. edn 4. Edited by Morgenson CE. Boston: Kluwer Academic Publishers; 1998: 263.
40. Murphy M, McGinty A, Godson C: Protein kinases C: potential targets for intervention in diabetic nephropathy. Curr Opin Nephrol Hypertens 1998, 7(suppl 5):563-570.
41. Ishii H, Tada H, Isogai S: An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-β and protein kinase C activity in cultured human mesangial cells. Diabetologia 1998, 41: 362-364.